Glenmark posts steady Q1 FY26 performance with growth in key markets

New Delhi: Glenmark Pharmaceuticals has reported its consolidated financial results for the first quarter ended June 30, 2025. The India business grew 3.7% year-on-year to Rs 12,399 mn, supported by continued demand across key therapeutic categories. North America revenue reached Rs 7,780 mn, reflecting 8.9% quarter-on-quarter growth driven by higher volumes and strong traction in injectable and partnered products.

The emerging markets segment remained stable with revenue of Rs 5,721 mn, showing a modest 0.2% year-on-year increase, while the Europe business posted Rs 6,678 mn in revenue, down 4.0% year-on-year due to market headwinds and currency fluctuations. The company reported EBITDA of Rs 5,805 mn, delivering a healthy 17.8% margin, and adjusted PAT of Rs 3,129 mn, resulting in a 9.6% margin, demonstrating its operational and bottom-line strength.

Commenting on the performance, Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd., said that the U.S. business delivered quarter-on-quarter growth on the back of injectable and partnered product launches. He added that the company’s Europe and Emerging Markets businesses have delivered over 25% and over 10% CAGR respectively during the last three years, and Glenmark expects these regions to return to double-digit growth from the second quarter onwards.

He emphasised that the recent IGI-AbbVie global licensing agreement for ISB 2001 validates the company’s innovation capabilities and expressed confidence in Glenmark’s strategy to drive growth across markets while advancing its branded, specialty, and innovative products to deliver long-term value for stakeholders.